Atara Biotherapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Atara Biotherapeutics

02/02/2024 11:15

* Atara Biotherapeutics Inc  ATRA.OQ   ATRA.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
6 (estimated) for the period ending December 31 2023
    * The Thousand Oaks California-based  company is expected to
report a 5,126.9% increase in revenue to $11.552 million from
$221 thousand a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Atara Biotherapeutics
Inc is
for a loss of 48 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atara
Biotherapeutics Inc is $2.90​, above​ its last closing price
of $0.83. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.66       -0.66      -0.66     Met     0.3
 Jun. 30 2023  -0.66       -0.67      -0.68     Missed  -1.1
 Mar. 31 2023  -0.38       -0.39      -0.72     Missed  -83.8​
 Dec. 31 2022  -0.49       -0.51      -0.72     Missed  -41.8
 ​​Sep.        -0.77       -0.78      -0.82     Missed  -4.5
 30 2022                                                
 Jun. 30 2022  -0.91       -0.93      -0.31     Beat    66.5​
 Mar. 31 2022  -0.99       -0.98      -0.87     Beat    11.2
 Dec. 31 2021  -0.67       -0.69      -0.96     Missed  -40
 This summary was machine generated February 2 at 11:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)